A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

QLS4131 for Injection.

Eligible participants will be assigned to 1 of the 9 dose groups ranging from 0.06 μg/kg to 600 μg/kg.

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY